Entrada Therapeutics (TRDA) Operating Margin (2023 - 2025)
Historic Operating Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2915.18%.
- Entrada Therapeutics' Operating Margin fell 28045100.0% to 2915.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.59%, marking a year-over-year decrease of 2244400.0%. This contributed to the annual value of 22.3% for FY2024, which is 247500.0% up from last year.
- As of Q3 2025, Entrada Therapeutics' Operating Margin stood at 2915.18%, which was down 28045100.0% from 2402.51% recorded in Q2 2025.
- Entrada Therapeutics' Operating Margin's 5-year high stood at 56.42% during Q2 2024, with a 5-year trough of 2915.18% in Q3 2025.
- In the last 3 years, Entrada Therapeutics' Operating Margin had a median value of 22.88% in 2023 and averaged 502.43%.
- Its Operating Margin has fluctuated over the past 5 years, first surged by 1461200bps in 2024, then plummeted by -28045100bps in 2025.
- Over the past 3 years, Entrada Therapeutics' Operating Margin (Quarter) stood at 11.72% in 2023, then crashed by -234bps to 15.69% in 2024, then tumbled by -18482bps to 2915.18% in 2025.
- Its Operating Margin stands at 2915.18% for Q3 2025, versus 2402.51% for Q2 2025 and 105.99% for Q1 2025.